2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on …
Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association …
Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
[HTML][HTML] Heart failure with mid-range or mildly reduced ejection fraction
G Savarese, D Stolfo, G Sinagra, LH Lund - Nature Reviews Cardiology, 2022 - nature.com
Left ventricular ejection fraction (EF) remains the major parameter for diagnosis,
phenotyping, prognosis and treatment decisions in heart failure. The 2016 ESC heart failure …
phenotyping, prognosis and treatment decisions in heart failure. The 2016 ESC heart failure …
2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with …
Abstract The 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart
Failure Treatment was created to provide a practical, streamlined resource for clinicians …
Failure Treatment was created to provide a practical, streamlined resource for clinicians …
Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction
CG Santos-Gallego, AP Vargas-Delgado… - Journal of the American …, 2021 - jacc.org
Background Large clinical trials established the benefits of sodium-glucose cotransporter 2
inhibitors in patients with diabetes and with heart failure with reduced ejection fraction …
inhibitors in patients with diabetes and with heart failure with reduced ejection fraction …
Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)
Background: Sodium-glucose cotransporter 2 inhibitors reduce the risk of heart failure
hospitalization and cardiovascular death in patients with heart failure and reduced ejection …
hospitalization and cardiovascular death in patients with heart failure and reduced ejection …
Cardiac natriuretic peptides
JP Goetze, BG Bruneau, HR Ramos, T Ogawa… - Nature Reviews …, 2020 - nature.com
Investigations into the mixed muscle–secretory phenotype of cardiomyocytes from the atrial
appendages of the heart led to the discovery that these cells produce, in a regulated …
appendages of the heart led to the discovery that these cells produce, in a regulated …
[HTML][HTML] Arterial stiffness and hypertension in the elderly
S Laurent, P Boutouyrie - Frontiers in cardiovascular medicine, 2020 - frontiersin.org
Hypertension prevalence increases with age. Age and high blood pressure are the two main
determinants of arterial stiffness. In elderly hypertensives, large arteries stiffen and systolic …
determinants of arterial stiffness. In elderly hypertensives, large arteries stiffen and systolic …
Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of …
WC Meijers, A Bayes‐Genis, A Mebazaa… - European journal of …, 2021 - Wiley Online Library
New biomarkers are being evaluated for their ability to advance the management of patients
with heart failure. Despite a large pool of interesting candidate biomarkers, besides …
with heart failure. Despite a large pool of interesting candidate biomarkers, besides …
Sacubitril/valsartan: neprilysin inhibition 5 years after PARADIGM-HF
KF Docherty, M Vaduganathan, SD Solomon… - Heart Failure, 2020 - jacc.org
Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), has been shown to
reduce the risk of cardiovascular death or heart failure hospitalization and improve …
reduce the risk of cardiovascular death or heart failure hospitalization and improve …